OISÍN BIOTECHNOLOGIES

Breakthrough Treatments for Age-Related Diseases

Oisín Biotechnologies' mission is to ameliorate age-related disease using our breakthrough SENSOlytic[®] gene therapy platform. This proprietary platform has been shown to selectively and efficiently eliminate senescent cells (SnCs) body-wide in multiple animal models.

We have demonstrated therapeutic benefit in both disease burden and lifespan. Our treatments are well tolerated in multiple species (mouse, rat, canine, primate) at doses well in excess of the anticipated human therapeutic dose.

Oisin's first indication will be targeting chronic kidney disease (CKD).

Limitations of Existing Therapies	Oisín Technology
 Small Molecule Drugs Side effects Toxicity from systemic administration Antibody Therapies Lack of validated targets on SnCs No compelling efficacy or safety data 	 Our SENSOlytic therapy kills SnCs <u>selectively</u> without damaging healthy cells or tissue Broad biodistribution <u>No dose limiting toxicity</u> even at <u>10X</u> the anticipated human therapeutic dose
Mechanism of Action	

- Proteo-Lipid Vehicles (PLVs) containing plasmid DNA are administered via i.v. infusion and distribute broadly throughout the body
- PLVs fuse with any cell they come in contact with and deliver their DNA payload directly to the cytoplasm.
- The DNA payload encodes and inducible Caspase 9 suicide gene that only activates in p16+ senescent cells
- Target cells are killed via apoptosis





Confidential

Oisín's Platform Demonstrates Significant Results

Technology in Action

Selective Killing of Targeted Cells



- **Green Cells** = Cells that are expressing the targeted gene and were treated with the SENSOlytic PLV
- **Red Cells** = Other cells that were treated with the SENSOlytic PLV but are not expressing the targeted gene
- <u>**Results:**</u> Targeted cells are selectively killed while the surrounding cells are spared

Proven Efficacy

Significant Increase in Lifespan Demonstrated in Aged Mouse Study



Significant Increased Bone Density in Treated Mice



Oisín Opportunity

- Oisín is taking a radically different approach to drug delivery
 - Broad delivery with a targeted payload with high specificity for disease causing cells
- Oisín's technology has meaningful advantages:
 - Significantly safer than other nanoparticle delivery systems
 - Far more cost-effective and scalable than viral delivery systems

- Lack of immunogenicity allows for repeat dosing compared to AAV and other viral platforms
- First indication is chronic kidney disease (CKD)
 - Huge unmet need
 - Plans to reach submit IND in 2021
- Oisín is currently raising a \$5M investment to complete IND enabling studies for Chronic Kidney Disease
- First tranche is already closed

This presentation does not constitute an offer to sell or the solicitation of an offer to buy securities. This presentation is preliminary and has been prepared and provided solely for informational purposes from information supplied by Oisín (the "Company"). Neither the Company, nor any of their employees, affiliates, or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of the information contained herein. By accepting this presentation, the recipient agrees that the information and data contained herein are confidential and may not be divulged to any person or entity or reproduced, disseminated or described, in whole or in part, except to the recipient's officers, directors, employees and agents in connection with evaluation of a transaction with the Company or as required by applicable law or with the prior written consent of the Company.



Confidential